High Flow Nasal Cannula for Stabilization of Extremely Premature Infants
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-2
SponsorCharles University, Czech Republic
About this trial
A prospective observational study evaluates the safety and efficacy of using High-Flow Nasal Cannula to stabilize extremely preterm infants immediately after birth. Following placental transfusion, high flow nasal cannula at 6-8 l/min is administered along with intermittent tactile stimulation. Criteria for switching to other interventions like continuous positive airway pressure or positive pressure ventilation are set for cases of persistent bradycardia or low Saturation of oxygen (SpO2).
Eligibility criteria
Qualifiers
Preterm infants born between 25+0 and 27+6 gestational weeks
Weight above 500 grams
Disqualifiers
Previable rupture of membranes,
Congenital malformations previable
Acute intrauterine hypoxia.
Trial design
Treatments tested in this trial
- High-Flow Nasal Cannula
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov